Assessment of the dynamics of immunological parameters at the beginning of therapy as prognostic and predictive factors in patients with melanoma
- Authors: Novik A.V1,2, Danilova A.B1, Nekhaeva T.L1, Emelyanova N.V1, Semenova A.I1, Latipova D.K.1, Teletaeva G.M1, Protsenko S.A1, Baldueva I.A1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- Saint Petersburg State Pediatric Medical University
- Issue: Vol 28, No 7 (2021)
- Pages: 118-126
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313188
- DOI: https://doi.org/10.18565/pharmateca.2021.7.118-126
- ID: 313188
Cite item
Abstract
Full Text
About the authors
A. V Novik
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University
Email: anovik@list.ru
Saint Petersburg, Russia
A. B Danilova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
T. L Nekhaeva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
N. V Emelyanova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
A. I Semenova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
D. Kh Latipova
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
G. M Teletaeva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
S. A Protsenko
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
I. A Baldueva
N.N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
References
- Suda K. Recent Advances in Cancer Immunotherapy. Biomolecules. 2021;11(2):335. Doi: 10.3390/ biom11020335
- Griffiths J.I., Wallet P., Pflieger L.T., et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A. 2020;117(27):16072-82. Doi: 10.1073/ pnas.1918937117.
- Новик А.В., Гирдюк Д.В., Кузнецова А.И. и др. Способ определения значимости различий результатов измерения субпопуляции лимфоцитов методом проточной цитофлюориметрии. Патент № RU 2720411 C1 от 29.04.2020.
- Fennemann F.L., de Vries I.J. M., Figdor C.G., et al. Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. Front Immunol. 2019:10:824. doi: 10.3389/fimmu.2019.00824.
- de Coana Y.P, Wolodarski M., Poschke I., et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539-53. doi: 10.18632/oncotarget.15368.
- Carnevalli L.S., Ghadially H., Barry S.T. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Front Immunol. 2021;12:633685. Doi: 10.3389/ fimmu.2021.633685.
- Huntington N.D., Cursons J., Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437-54. doi: 10.1038/s41568-020-0272-z.
- Foureau D.M., Amin A., White R.L., et al. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome. Cancer Immunol Immunother. 2014;63(12):1329-1340. Doi: 10.1007/ s00262-014-1605-0.
- Новик А.В., Проценко С.А., Балдуева И.А. Использование оценки состояния врожденной иммунной системы у больных со злокачественными солидными опухолями в качестве предиктивных или прогностических факторов: систематический обзор Эффективная фармакотерапия. 2020;16(8):58-77.
- Coffelt S.B., Wellenstein M.D. de Visser K.E. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431-46. Doi: 10.1038/ nrc.2016.52.
- Shaul M.E., Fridlender Z.G. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601-20. Doi: 10.1038/ s41571-019-0222-4.
- Ouwerkerk W, van den Berg M, van der Niet S, et al. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Res. 2019;29(5):453-64. doi: 10.1097/CMR.0000000000000589.